meRfi®-GM
Asthma
Welcome to meRfi-GM!
meRfi-GM provides you with up-to-date, evidence-based insights on the gut microbiota and related health topics.
Access our ever-expanding digital library and get personalized answers through our interactive AI chat platform.
Start your free trial and transform your understanding of the gut microbiota today!
Navigation
Contents
Asthma is a condition marked by reversible airway obstruction, inflammation, and hyperresponsiveness
Group 2 ILCs (ILC2) or Interleukin-4 (IL-4), Interleukin-5 (IL-5), and Interleukin-13 (IL-13)-producing CD4+ Th2 cells cause chronic airway inflammation in many asthmatics
Type 2 cytokines promote hallmarks of the disease, such as eosinophilia, mucus hypersecretion, bronchial hyperreactivity (BHR), IgE production, …
References (Sources)
- Airway remodeling heterogeneity in asthma and its relationship to disease outcomes
- Allergen immunotherapy modulates sensitivity of Treg cells to apoptosis in a rat model of allergic asthma
- Asthma
- Regulation of Immune Responses by Nonhematopoietic Cells in Asthma
- Strategies Targeting Type 2 Inflammation: From Monoclonal Antibodies to JAK-Inhibitors
- The house dust mite allergen Der p1 catalytically inactivates alpha 1-antitrypsin by specific reactive centre loop cleavage: a mechanism that promotes airway inflammation and asthma
- The role of the microbiome in childhood asthma